第二代药物支架对冠心病介入治疗的有效性及安全性分析被引量：9

下载PDF

导出

摘要目的比较第二代药物洗脱支架Endeavor和Xience在冠心病介入治疗中的临床疗效,评价第二代药物洗脱支架的安全性和有效性。方法回顾性分析2010年3月—2013年9月初次行择期PCI术的100例冠心病患者。均采用佐他莫司洗脱支架(Endeavor支架)或雅培公司依维莫司支架(XienceⅤ支架)单一种类支架治疗。分析两组临床资料、冠脉造影特征、支架植入情况以及术后1个月、6个月、1年的临床、影像学资料。结果两组术后1年均未见支架内血栓形成、支架内再狭窄;术后6个月及1年与术前相比,左室射血分数(LVEF)值升高且有统计学意义;两组术后心血管事件发生率相比无统计学意义。结论第二代药物洗脱支架Endeavor和Xience在冠心病患者择期介入治疗中具有相似的临床疗效,且均安全可靠。

作者张永胜

机构地区山西省晋城煤业集团总医院

出处《中西医结合心脑血管病杂志》 2015年第13期1565-1567,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

关键词冠心病药物洗脱支架依维莫司支架佐他莫司支架支架内再狭窄支架内血栓形成

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献8

1Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus - eluting stent implantation: Five - year outcome of the j - cypher registryFJ~. Circulation,2012,125(4) :584- 591.
2Meredith IT,Ormiston J, Whitbourn R, et al. ENDEAVOR I In- vestigators. Four - year clinical follow - up after implantation of the endeavor zotarolimus- eluting stent: ENDEAVOR I,the first- in - human studyFJ~. Am J Cardioh 2007,100(8B) : 56M - 61M.
3Fajadet J,Wijns W, Laarman GJ, et al. ENDEAVOR l] investi- gators, randomized, double - blind, multicenter study of the en-deavor zotarolimus - eluting phosphorylcholine - encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial[J]. Circulation, 2006,114(8) : 798 - 806.
4Kandzari DE,Leon MB,Popma JJ, et al. ENDEAVOR HI Inves- tigators. Comparison of zotarolimus - eluUng and sirolimus - elu ting stents in patients with native coronary artery disease: A ran- domized controlled trial[J]. J Am Coil Cardiol, 2006, 48(12): 2440 - 2447.
5Martin B, Neville K, Nicolo P, et al. A randomized comparison of the endeavor zotarolimus - eluting stent versus the TAXUS pacli- taxel- eluting stent in de novo native coronary lesions. 12 - month outcomes from the ENDEAVOR IV trial[J]. J Am Coil Car- diol, 2010,55: 543 - 554.
6Nikolsky E, Lansky A J, Sudhir K, et al. SPIRIT IV trial design: A large - scale randomized comparison of everolimuseluting stents and paclitaxel - eluting stents in patients with coronary artery disease[J]. Am Heart J, 2009,158(4) : 520 - 526.
7Kedhi E,Joesoef KS, McFadden E, etal. Second - generation everolimus - eluting and paclitaxel - eluting stent sin real - life practice (COMPARE): A randomised trial[J]. Lancet,2010, 375 (9710) ;201 - 209.
8Patrick W, Sigmund S, Scot G, etal. Comparison of zotarolimus - eluting and everolimus - eluting coronary stentsrJ~. N Engl J Med,2010,363:136 - 146.